GWAG
BMRN icon

Garrett Wealth Advisory Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Garrett Wealth Advisory Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-87
Closed -$5.86K – 127
2019
Q3 		$5.86K Buy
+87
New +$6.7K ﹤0.01% 343

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Garrett Wealth Advisory Group's BMRN Position: Q4 2019 in Review

Garrett Wealth Advisory Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 87 shares — an estimated $5.86K sold.

Garrett Wealth Advisory Group first reported a position in BMRN in Q3 2019 and held it in 1 quarter. The position peaked at $5.86K in Q3 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Garrett Wealth Advisory Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Garrett Wealth Advisory Group sold 87 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $5.86K.
  • Garrett Wealth Advisory Group first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Garrett Wealth Advisory Group's BioMarin Pharmaceuticals position peaked at $5.86K in Q3 2019.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Garrett Wealth Advisory Group's 13F filing for Q4 2019, filed 28 Jan 2020.